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Summary
Background Corticosteroids are considered to be particularly effective in reducing nasal congestion
and are therefore recommended as ﬁrst-line treatment in allergic rhinitis patients with moderate to
severe and/or persistent symptoms.
Objective We compared the clinical efﬁcacy of ﬂuticasone propionate aqueous nasal spray
(FPANS) 200mg given once daily, administered in mono-therapy or combined therapy with a H1
receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the
combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to
Parietaria during natural pollen exposure. In addition, we examined the effect of the treatment on
eosinophil counts and eosinophil cationic protein (ECP) in nasal lavage performed at beginning of
season, during season and at the end of the season.
Methods One hundred patients aged 12–50 years (mean  SD 31.8  9.6) with a history of
moderate to severe Parietaria pollen-induced seasonal allergic rhinitis were selected. A randomized,
double-blind, double dummy, placebo (PLA)-controlled, parallel-group study design was used.
Patients were treated FPANS 200mg once daily (n5 20) or with FPANS 200mg once daily, plus CTZ
(10mg) in the morning (n5 20), or with FPANS 200mg once daily, plus MSK (10mg) in the evening
(n5 20) or with CTZ (10mg) in the morning plus MSK in the evening (n5 20) or matched PLA
(n5 20). Assessment of efﬁcacy was based on scores of daily nasal symptoms and on eosinophil
counts and ECP in nasal lavage.
Results All treatments showed signiﬁcant differences (Po0.001) compared with PLA in terms of
total symptom, rhinorrhea, sneezing and nasal itching scores. Concerning nasal congestion on
waking and daily only the groups treated with FPANS in mono-therapy or in combined therapy
showed signiﬁcant differences compared with PLA. Comparing the group treated with FPANS alone
and the groups treated with FPANS plus CTZ, we found signiﬁcant differences for total symptom
score (P5 0.04) and for nasal itching (P5 0.003). The comparison between FPANS plus CTZ and
FPANS plus MSK showed signiﬁcant difference for nasal itching (P5 0.003). Finally, there were
signiﬁcant differences between the group treated with FPANS and the group treated with CTZ plus
MSK for total symptom score (P5 0.009), for nasal congestion on waking (Po0.001) and nasal
congestion daily (Po0.001). Also the comparisons between the group treated with FPANS plus CTZ
and the group treated with CTZ plus MSK demonstrated signiﬁcant differences (Po0.001) for total
symptom, for nasal congestion on waking and for nasal congestion on daily, for rhinorrhea
(P5 0.04) and for nasal itching (P5 0.003) scores. Concerning the comparison between the group
treated with FPANS plus MSK and the group treated with CTZ plus MSK we found signiﬁcant
differences for total symptom score (P5 0.005), for nasal congestion on waking (Po0.001) and for
nasal congestion on daily (Po0.001). No other differences were observed between the groups.
Concerning blood eosinophil counts, signiﬁcant differences were found between the treatments with
FPANS in mono-therapy or in combined therapy with PLA group during and at the end of the
season (P5 0.0003 and Po0.0001, respectively). Concerning eosinophils and ECP in nasal lavage,
all treatments showed signiﬁcant differences (Po0.001) compared with PLA. Besides, there were
signiﬁcant differences (Po0.001) between the groups treated with FPANS alone or in combined
therapy and the group treated with CTZ plus MSK.
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Conclusion The results of this comparative study demonstrate that FPANS is highly effective for
treating patients affected by allergic rhinitis, with efﬁcacy exceeding that of CTZ plus MSK in
combined therapy. In addition, the regular combined therapy of FPANS plus CTZ or plus MSK
would not seem to offer substantial advantage with respect to FPANS in mono-therapy in patients
affected by seasonal allergic rhinitis.
Keywords cetirizine, eosinophil cationic protein, eosinophils, ﬂuticasone propionate, montelukast,
nasal lavage, Parietaria, pollen season
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Introduction
The current guidelines from the European Academy of
Allergy and Clinical Immunology (EAACI) working party
on the management of rhinitis and the Allergic Rhinitis and
its Impact on Asthma (ARIA) initiative state that antihista-
mines are ﬁrst-line therapy for allergic rhinitis [1, 2].
However, these guidelines also point out that antihistamines,
although effective at reducing rhinorrhea, sneezing, itching
and eye symptoms, are relatively ineffective at reducing nasal
blockage [1, 2]. However, corticosteroids are considered to be
particularly effective in reducing nasal congestion and are
therefore recommended as ﬁrst-line treatment in allergic
rhinitis patients with moderate to severe and/or persistent
symptoms [1, 2]. Furthermore, a meta-analysis performed in
1998, looking at the effect of a number of ﬁrst- and second-
generation antihistamines vs. intranasal corticosteroids on
nasal blockage, showed that steroids performed better in
every study analysed, with an overall signiﬁcant difference in
the meta-analysis [3].
A recent development in the treatment of asthma has been
the introduction of leukotriene receptor antagonists (mon-
telukast (MSK), zaﬁrlukast and pranlukast). They are supe-
rior to placebo (PLA) in improving the symptoms of asthma
but are generally not as effective as steroids and their place in
the management of asthma is still controversial [4–6].
A number of studies have shown that the combination of
antihistamines and antileukotrienes in allergic rhinitis has
shown additional efﬁcacy over single treatment [7–9]. Other
studies have also shown combination therapy to be as
effective as certain intranasal corticosteroids [8]. A further
study, looking at the combination of MSK and cetirizine
(CTZ) against the intranasal corticosteroid budesonide,
also showed a signiﬁcant reduction in all allergic rhi-
nitis symptoms, with no difference between the treatment
groups [9].
No study has compared topical corticosteroids in mono-
therapy or in combined therapy with mediator antagonist in
patients affected by allergic rhinitis.
In this study, we compared the clinical efﬁcacy of
ﬂuticasone propionate aqueous nasal spray (FPANS) 200mg
given once daily, administered in mono-therapy or combined
therapy with a H1 receptor antagonist (CTZ) or with a
leukotriene antagonist (MSK), and the combined therapy of
CTZ plus MSK in the treatment of patients affected by
allergic rhinitis to Parietaria during natural pollen exposure.
In addition, we examined the effect of the treatments on
eosinophil counts and eosinophil cationic protein (ECP) in
nasal lavage performed at beginning of season, during season
and at the end of the season.
Materials and methods
Population
One hundred patients aged 12–50 years (mean  SD
31.8  9.6) with a history of moderate to severe Parietaria
pollen-induced seasonal allergic rhinitis were selected, by
chart review, from outpatients of Departments of Medicina
Clinica e Patologie Emergenti of University of Palermo and
Medicina Clinica e Sperimentale of University of Verona
(Italy). Patients were recruited based on a clinical history of
allergic rhinitis, of the presence of positive skin prick test
response to Parietaria pollen and ﬁnally of at least 2 years
duration symptoms during Parietaria season. Patients were
excluded if they had taken the following drugs: long-acting
histamine antagonists within the past 6 weeks; inhaled,
intranasal, or systemic corticosteroids or inhaled sodium
cromoglycate within the past 4 weeks. Other exclusion criteria
were the presence of concurrent infection of the paranasal
sinuses, and/or of the upper or lower respiratory tract, and/or
asthma, nasal surgery within the past year, structural nasal
abnormalities or concurrent diseases that could interfere with
the validity of the study results. Patients were also excluded if
they were pregnant or lactating.
Before the study began, approval was obtained from the
Ethic Committees of the two centres involved. Written
informed consent was obtained from all enrolled patients.
Study design
A randomized, double-blind, double dummy, PLA-con-
trolled, parallel-group study design was used. Patients, in
each centre, received the following treatments:
1. FPANS, 200mg – aqueous nasal spray – ﬂuticasone
propionate 50mg/actuation, two actuations into each
nostril in the morning plus PLA of CTZ in the morning
and plus PLA of MSK in the evening.
2. FPANS, 200mg – aqueous nasal spray – ﬂuticasone
propionate 50mg/actuation, two actuations into each
nostril in the morning plus CTZ 10mg in the morning
and plus PLA of MSK in the evening.
3. FPANS, 200mg – aqueous nasal spray – ﬂuticasone
propionate 50mg/actuation, two actuations into each
nostril in the morning plus MSK 10mg 1 day in the
evening plus PLA of CTZ in the morning.
4. CTZ 10mg 1 day in the morning plus MSK 10mg in the
evening plus PLA of ﬂuticasone propionate nasal spray.
5. PLA of ﬂuticasone propionate plus PLA of CTZ plus PLA
of MSK.
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The pharmacist of University Hospital of Verona has pre-
pared a speciﬁc set with the treatments in study. The investi-
gators and patients were blinded to the contents of the sets.
The pharmacist using commercially tablets of CTZ (Zirtecs,
UCB, Italy) or tablets of MSK (Singulairs, Merk Sharp and
Dome, Italy) or ﬂuticasone propionate nasal aqueous spray
(Flixonases GlaxoSmithKline, Italy) or tablets of PLA or
PLA of ﬂuticasone propionate nasal aqueous spray prepared
the sets. As regards the PLA of ﬂuticasone propionate nasal
aqueous spray, the pharmacist using empty bottle of ﬂuti-
casone propionate prepared PLA of nasal spray using saline
solution.
The treatment period started just before the beginning of
the pollen season, without any run-in. Patients were treated
for 6 weeks.
Each patient attended the clinics on four different occa-
sions. This included an initial clinical visit, a second visit after
3 weeks of treatment and a ﬁnal visit after 6 weeks of treat-
ment (i.e. visit 3) and 2 weeks after the end of the treatment
period (follow-up, visit 4).
At visit 1 symptom scores of rhinitis were assessed by pa-
tients by means of a visual analogical scale (0–12), and nasal
lavage was performed. Enrolled patients received a daily
record diary for nasal and eye symptoms. The study was con-
ducted during the Spring 2001. Two centres documented local
daily pollen counts throughout the study period.
The patients (10 patients for each treatment) enrolled in
Palermo started the treatments at ﬁrst week of April, whereas
the patients (10 patients for each treatment) enrolled in
Verona started the treatments at last week of April.
Assessment of symptoms
Patients were instructed to record their daily symptoms on
diary cards. Nasal symptoms included nasal blockage on
waking and during the day, rhinorrhea, sneezing and itching.
Eye symptoms included watering and/or irritation. Nasal
congestion was scored as follows: (0) not present; (1) slightly
difﬁcult breathing through the nose; (2) moderately difﬁcult
breathing through the nose; (3) very difﬁcult or impossible
breathing through the nose. Any other recorded symptom
was scored as follows: (0) none; (1) mild (occasionally pre-
sent); (2) moderate (rather frequent); (3) severe (persistent).
Rescue medications included levocabastine nasal spray
(50mg per puff) and sodium cromoglycate eye-drops (4%
w/v). No other medication for rhinitis was permitted during
the trial.
Eosinophil blood counts
A venous blood sample was collected and the eosinophils
were counted in a Fuchs Rosenthal chamber after staining
with eosinophil staining solution and results were expressed
as eosinophils  10 3mL [10, 11].
Nasal cytology
Nasal lavage was performed using a disposable metered-dose
nasal inhaler (Markos, Monza, Italy) ﬁlled with sterile, room
temperature, normal saline solution. The device consisted of a
plastic cup with two rooms. The central compartment was
ﬁlled with sterile saline solution with a syringe; the external
compartment collected the liquid after washing. Total input
of saline solution was approximately 8mL (4mL in each
nostril for 5min). To collect the nasal washings, the subjects
were instructed to actively breathe during a Valsalva
manoeuvre to harvest nasal ﬂuid in the cup. Obtained
samples were stored on ice and centrifuged at 400g for
10min at 4 1C and supernatant aliquots were stored at
 80 1C. The individual variation in the recovered vs.
introduced volume was 86%  8%. Nasal eosinophil counts
were performed on nasal lavage. One cytospin slide for each
sample (1  104 cells in 170mL for slide) was centrifuged at
10  g for 10min in a Shandon cytocentrifuge (Shandon
Southern Ltd, Runcorn, Cheshire, UK). Slides were imme-
diately ﬁxed in 95% ethyl alcohol and dipped in Wright–
Giemsa stain. The slides were examined under oil immersion
by light microscopy at magniﬁcation of  400. Eosinophil
counts were expressed as percentage of 300 cells counted. All
specimens were examined by the same microscopist [12, 13].
ECP nasal fluid
The assay of nasal ECP was performed with a Fluorescent
Enzyme Immunoassay (FEIA) using the Pharmacia CAPTM
system (Pharmacia, Uppsala, Sweden). The detection limit
was 2 ng/mL, and the interassay variation was less of 5.9%
[12, 13].
Pollen count
Pollen was collected and measured daily throughout the study
period. Pollen amounts were expressed as median of grain per
cubic metre. Parietaria pollen recorded during the period
study is shown in Fig. 1.
Statistical analysis
The primary assessment of efﬁcacy was based on the
differences between each treatment group vs. PLA for total
symptom score and for every symptom of the rhinitis. Data
are presented as mean (95% conﬁdence interval, CI) of the
mean of individual score. ANCOVA was used to account for
any inﬂuence on treatment response of changes in pollen level
over time. Adjusted values were subsequently averaged by
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Fig. 1. Median of daily pollens counts for Parietaria during Spring 2001 in
Sicily and Veneto, at site where the study was conducted.
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patient over the entire observation period. Averages by
patient were examined using a ‘mixed-effects’ ANOVA model
with, as main factors, the treatments (as ﬁxed effect) and the
centres (as random effect); F-values were calculated using the
mean-squares of the interaction ‘centres  treatments’ as the
error term. Differences between means were performed by
Bonferoni’s multiple range test (set at 95% CI). Power ana-
lysis on post hoc comparisons was performed by the ‘GPower’
software package [14]. Comparisons are only denoted as
being signiﬁcant (Po0.05, two-tailed) or not signiﬁcant if
our sample size exceeded the minimum sample size resulting
from power analysis at b5 0.80.
Blood eosinophil counts were expressed as mean  SD. The
nasal eosinophils and ECP were presented as mean (95% CI)
of the nasal eosinophils and nasal ECP at the end of the
season minus nasal eosinophils and nasal ECP before the
season. Differences between means were performed by
Bonferoni’s multiple range test (set at 95% CI). All other
analyses were performed using SYSTAT 10 software
package.
Results
One hundred patients were randomized to treatments, 20
patients for each treatment (see above). For each group 10
patients were enrolled in Palermo and 10 in Verona. All
patients began the treatment at the same week (see Study
design) and all patients concluded the whole study, including
the follow-up period. The baseline characteristics, with
respect to duration of seasonal rhinitis, age of patients and
mean blood eosinophil count are shown in Table 1.
Assessment of efficacy
Figures 2a–f and Table 2 show total symptom, nasal
congestion on waking and daily, rhinorrhea, sneezing and
nasal itching scores, respectively. Data are reported as mean
(95% CI) of the mean of individual score during the
treatment period. Table 2 shows the mean difference (95%
CI for difference) between the treatments.
All treatments showed signiﬁcant differences (Po0.001)
compared with PLA in terms of total symptom, rhinorrhea,
sneezing and nasal itching scores. Concerning nasal conges-
tion on waking and daily only the groups treated with
FPANS in mono-therapy or in combined therapy showed
signiﬁcant differences compared with PLA. Besides, there was
no signiﬁcant difference between CTZ plus MSK vs. PLA,
concerning both nasal congestion on waking and daily.
Comparing the groups treated with FPANS alone and the
groups treated with FPANS plus CTZ, we found signiﬁcant
differences for total symptom score (P5 0.04) and for nasal
itching (P5 0.003). The comparison between FPANS plus
CTZ and FPANS plus MSK showed signiﬁcant difference for
nasal itching (P5 0.003).
Finally, there were signiﬁcant differences between the group
treated with FPANS and the group treated with CTZ plus
MSK for total symptom score (P5 0.009), for nasal
congestion on waking (Po0.001) and nasal congestion daily
(Po0.001). Also the comparisons between the group treated
with FPANS plus CTZ and the group treated with CTZ plus
MSK demonstrated signiﬁcant differences (Po0.001) for
total symptom, for nasal congestion on waking and for nasal
congestion on daily, for rhinorrhea (P5 0.04) and for nasal
itching (P5 0.003) scores. Concerning the comparison
between the group treated with FPANS plus MSK and the
group treated with CTZ plus MSK we found signiﬁcant
differences for total symptom score (P5 0.005), for nasal
congestion on waking (Po0.001) and for nasal congestion on
daily (Po0.001). No other differences were observed between
the groups.
The median percentage of days without eye symptoms in
the ﬁve treatments was not statistically different (FPANS
group 60.2 days; FPANS plus CTZ group 72.1days; FPANS
plus MSK group 70.5 days; CTZ plus MSK group 73.4 days;
PLA group 58.4 days). Finally, the use of rescue medication,
expressed as the median of days without the use of
levocabastine nasal spray, was signiﬁcantly lower in the
groups treated with FPANS in mono-therapy (96.4 days) or
in combined therapy FPANS plus CTZ group (97.0 days) and
FPANS plus CTZ group (95.7 days) than either the CTZ plus
MSK group (92.7, P5 0.03) or PLA group (68.1, Po0.001).
Blood eosinophil counts
No signiﬁcant differences were found in the blood eosinophil
counts between the groups in the samples taken before the
beginning of season (Table 3). Signiﬁcant differences were
found between the treatments with FPANS in mono-therapy
or in combined therapy with PLA group during and at the
end of the season (P5 0.0003 and Po0.0001, respectively).
Table 1. Baseline characteristics
FPANS group
(n5 20)
FPANS plus CTZ group
(n5 20)
FPANS plus MSK group
(n5 20)
CTZ plus MSK group
(n5 20)
PLA group
(n5 20)
Male/female ratio 12/8 8/12 6/14 9/11 6/14
Mean age (years) 30.5 32.8 27.1 34.3 34.2
Age range (years) 15–50 14–48 12–48 20–44 14–37
Duration of rhinitis
2–4 years 11 11 11 12 10
5–9 years 05 06 06 05 04
X10 years 04 03 03 03 06
FPANS, fluticasone propionate aqueous nasal spray; CTZ, cetirizine; MSK, montelukast; PLA, placebo.
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Nasal lavage
Eosinophils Figure 3 shows the mean difference (95% CI)
of nasal percentage of eosinophils at the end of the season
minus the nasal percentage of eosinophils before the season.
All treatments showed signiﬁcant differences (Po0.001)
compared with PLA. There were no signiﬁcant differences
between the group treated with FPANS and the group treated
with FPANS plus CTZ and the group treated with FPANS
plus MSK. Besides, there were signiﬁcant differences (Po
0.001) between the groups treated with FPANS alone or in
combined therapy and the group treated with CTZ plus MSK.
ECP The mean difference (95% CI) of nasal ECP at the end
of the season minus the nasal ECP before the season is
reported in Fig. 4. All treatments showed signiﬁcant
differences (Po0.001) compared with PLA. There were no
signiﬁcant difference between the group treated with FPANS
and the group treated with FPANS plus CTZ and the group
treated with FPANS plus MSK. There were signiﬁcant
differences (Po0.001), instead, between the groups treated
with FPANS alone or in combined therapy and the group
treated with CTZ plus MSK.
Safety
A low incidence of adverse events was observed in the study.
All adverse events were rated as mild. Respiratory symptoms
were reported by seven patients in PLA group. Exacerbation
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Fig. 2. (a–f) Total symptom, nasal congestion on waking and daily, rhinorrhea, sneezing and nasal itching scores, respectively. Data are reported as mean
(95% confidence interval, CI) of the mean of individual score during the treatment period. The comparison between the treatments are reported in Table 2.
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Table 2. Mean values for FPANS, FPANS plus CTZ, FPANS plus MSK, CTZ plus MSK and PLA (95% CI for mean) and mean differences between the
treatments for total symptom score (out of 12) nasal blockage on waking (out of 3) and daily (out of 3), rhinorrhea (out of 3), sneezing (out of 3) and nasal itching
(out of 3)
Treatments
Subjective symptoms of rhinitis
Mean (95% CI)
TSS
Nasal congestion
on waking
Nasal congestion
daily Rhinorrhea Sneezing Nasal itching
FPANS 3.0 (2.8–3.1) 0.8 (0.7–0.9) 0.9 (0.8–0.9) 0.5 (0.5–0.6) 0.9 (0.8–0.9) 0.6 (0.5–0.7)
FPANS plus CTZ 2.8 (2.6–2.9) 0.7 (0.7–0.8) 0.8 (0.8–0.9) 0.6 (0.5–0.6) 0.8 (0.7–0.8) 0.5 (0.4–0.5)
FPANS plus MSK 3.0 (2.8–3.1) 0.7 (0.7–0.8) 0.8 (0.8–0.9) 0.6 (0.5–0.6) 0.8 (0.8–0.9) 0.6 (0.6–0.7)
CTZ plus MSK 3.3 (3.1–3.5) 1.2 (1.2–1.3) 1.2 (1.2–1.3) 0.5 (0.5–0.6) 0.8 (0.7–0.9) 0.6 (0.6–0.7)
PLA 4.7 (4.5–4.9) 1.3 (1.2–1.3) 1.2 (1.1–1.3) 1.3 (1.2–1.3) 1.1 (1.1–1.2) 0.9 (0.8–0.9)
Comparisons
Mean differences between the treatments (95% CI for difference)
Differences FPANS vs. PLA  1.6 0.5  0.3 0.7 0.3  0.2
( 1.8 to 1.4) (0.5 to –0.4) ( 0.4 to –0.3) (0.7 to 0.6) (0.3 to 0.2) ( 0.3 to 0.1)
Po0.001 Po0.001 Po0.001 Po0.001 Po0.001 Po0.001
Differences FPANS vs. FPANS plus CTZ 0.2 0.06 0.04 0.04 0.08 0.1
(0.08 to –0.4) (0.01 to 0.1) ( 0.03 to 0.1) (0.88 to 0.006) (0.008 to 0.1) (0.06 to 0.2)
P5 0.04 P5NS P5NS P5NS P5NS P5 0.003
Differences FPANS vs. FPANS plus MSK 0.02 0.05 0.04 0.02 0.02  0.02
( 0.1 to 0.2) (0.02 to 0.1) ( 0.03 to 0.1) (0.06 to 0.02) (0.04 to 0.1) ( 0.09 to 0.05)
P5NS P5NS P5NS P5NS P5NS P5NS
Differences FPANS vs. FPANS plus MSK 0.02 0.02 0.02 0.02 0.02 0.02
( 0.1 to 0.2) (0.1 to 0.2) ( 0.1 to 0.2) (0.1 to 0.2) (0.1 to 0.2) ( 0.1 to 0.2)
P5NS P5NS P5NS P5NS P5NS
Difference FPANS vs. CTZ plus MSK  0.3 0.4  0.3 0.02 0.04 0.002
( 0.5 to 0.07) (0.5 to –0.3) ( 0.4 to –0.2) (0.01 to 0.07) (0.03 to 0.1) ( 0.07 to 0.07)
P5 0.009 Po0.001 Po0.001 P5NS P5NS P5NS
Diffrences FPANS plus CTZ vs. PLA  1.8 0.5  0.4 0.6 0.3  0.4
( 2.1 to 11.6) (0.6 to  0.4) ( 0.4 to 0.3) (0.7 to 0.6) (0.4 to 0.3) ( 0.4 to 0.3)
Po0.001 Po0.001 Po0.001 Po0.001 Po0.001 Po0.001
Difference FPANS plus CTZ vs. FPANS plus MSK  0.1 0.005  0.0001 0.01 0.05  0.1
( 0.4 to 0.01) (0.08 to 0.06) ( 0.07 to 0.07) (0.02 to 0.06) (0.1 to 0.01) ( 0.2 to 0.08)
P5NS P5NS P5NS P5NS P5NS Po0.001
Difference FPANS plus CTZ vs. CTZ plus MSK  0.5 0.5  0.4 0.07 0.04  0.1
( 0.7 to –0.2) (0.6 to –0.4) ( 0.4 to –0.3) (0.02 to 0.1) (0.1 to 0.03) ( 0.2 to 0.06)
Po0.001 Po0.001 Po0.001 P5 0.04 P5NS P5 0.003
Difference FPANS plus MSK vs. PLA  1.6 0.5  0.4 0.7 0.3  0.2
( 1.9 to 1.4) (0.6 to –0.4) ( 0.5 to 0.3) (0.7 to  0.6) (0.3 to 0.2) ( 0.3 to 0.1)
Po0.001 Po0.001 Po0.001 Po0.001 Po0.001 Po0.001
Difference FPANS plus MSK vs. CTZ plus MSK  0.3 0.5  0.3 0.05 0.01 0.02
( 0.5 to –0.09) (0.7 to –0.2) ( 0.5 to –0.4) (0.003 to 0.09) (0.06 to 0.08) ( 0.05 to 0.09)
P5 0.005 Po0.001 Po0.001 P5NS P5NS P5NS
Difference CTZ plus MSK vs. PLA  1.3 0.03  0.02 0.7 0.3  0.2
( 1.5 to 1.1) (0.1 to 0.04) ( 0.09 to 0.04) (0.8 to  0.7) (0.4 to 0.2) ( 0.3 to 0.1)
Po0.001 P5NS P5NS Po0.001 Po0.001 Po0.001
CTZ, cetirizine; MSK, montelukast; PLA, placebo; TSS, total symptom score; CI, confidence interval; NS, not significant.
Table 3. Mean blood eosinophil counts (  SD)  103mL obtained in five treatment groups
FPANS group
(n5 20)
FPANS plus CTZ group
(n5 20)
FPANS plus MSK group
(n5 20)
CTZ plus MSK group
(n5 20)
PLA group
(n5 20)
Before beginning of season 0.196  0.025 0.195  0.027 0.194  0.024 0.193  0.028 0.195  0.024
During season 0.198  0.020* 0.196  0.026* 0.196  0.023* 0.201  0.019 0.216  0.026
At the end of the season 0.185  0.023w 0.195  0.026w 0.195  0.021w 0.197  0.024 0.233  0.033
FPANS, fluticasone propionate aqueous nasal spray; CTZ, cetirizine; MSK, montelukast; PLA, placebo.
*Po0.0003 compared with placebo. wPo0.0001 compared with placebo.
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of nasal symptoms after treatment (follow-up period) was
reported only in one patient in the PLA group.
Discussion
The inﬂammatory cell changes are evident in relationship to
clinical disease expression, and the symptoms of rhinitis, that
is, nasal itching, sneezing, rhinorrhoea, nasal congestion and
loss of sense of smell, may be explained on the basis of
mediator release from inﬂammatory cells [12, 15–19]. How-
ever, end organ receptor antagonist, as anti-H1 [12, 20] and
antileukotriene administered in mono-therapy, does not give
a control of symptoms [13, 21, 22]. The nose is a small organ
comprising less than 1% of total body mass and surface area,
and it is therefore logical to conﬁne treatment of rhinitis to
the diseased organ with topical drugs [15, 23].
The results of this comparative study demonstrate that
ﬂuticasone propionate regularly administered once daily is
more effective for the treatment of nasal symptoms in patients
with allergic rhinitis than CTZ plus MSK given once day
orally. As regards nasal symptoms improving, the combina-
tion of FPANS with CTZ or with MSK failed to produce a
substantial advantage with respect to FPANS administered in
mono-therapy. In addition, FPANS treatment, both in
mono-therapy and in combined therapy, prevents eosinophil
increase in the nose during pollen season as measured in nasal
lavage, whereas the use of mediator antagonists in combined
therapy, failed to produce this effect. The same results were
obtained by analysing ECP levels in nasal lavage of the
different groups. In fact, ECP values in the nasal lavages were
unchanged only in the groups treated with FPANS, whereas
signiﬁcant increases, during pollen season, were observed in
the groups treated with CTZ plus MSK and PLA.
Our study conﬁrms that topical treatment with glucocorti-
costeroid reduces obstruction on waking and during the day,
rhinorrhea, sneezing and itching and that its clinical efﬁcacy
on the ﬁrst two symptoms was greater than that produced by
antireceptor antagonists [12, 20–22, 24–26]. It is noteworthy
that patients who received FPANS, in mono-therapy or in
combined therapy, were free from nasal congestion in
approximately 40% of the scheduled period, without
signiﬁcant difference with respect to the groups treated with
combination therapy (i.e. FPANS plus CTZ and FPANS plus
MSK). These results suggest that this effect is due to the
topical corticosteroid. In addition to the control of the
allergic nasal symptoms FPANS, in mono-therapy appears to
be not different from FPANS in combined therapy for the use
of rescue medication. On the contrary, the use of rescue
medication was higher in the subjects treated with antirecep-
tors antagonist in combined therapy. However, it should be
noted that most patients included in the PLA group refrained
from taking levocabastine nasal spray. This phenomenon has
been previously noted in other clinical studies [20].
The effectiveness of topical corticosteroids, as FPANS, for
the management of allergic rhinitis is most likely related to
multiple pharmacological actions of these drugs on inﬂam-
matory cells and on nasal mucosa cells. Besides, topical
corticosteroids have proven efﬁcacy in the treatment of
allergic rhinitis and their regular administration has been
shown to inhibit both the immediate and late response to
allergen provocation [23]. They inhibit the transcription of
several cytokines and adhesion molecules that are relevant in
rhinitis, including IL-5, IL-13, eotaxin and intercellular
adhesion molecule-1, involved in the migration of eosinophils
in the nasal mucosa and in their activity [12, 27–29]. A large
number of clinical studies have shown equal efﬁcacy of
topical corticosteroids on all three major symptoms of allergic
rhinitis, that is, sneezing, watery rhinorrhea and nasal
obstruction, in contrast to antihistamine treatment, which
has little effect on nasal obstruction [1, 2]. In fact, topical
steroids, but not H1-antihistamines and leukotriene antago-
nists, in mono-therapy, control the eosinophils inﬂux,
responsible for persistent nasal symptoms [21, 22].
On the other hand, MSK mono-therapy has demonstrated
clinical beneﬁts in asthma, because it reduced allergen-
induced early- and late-phase bronchoconstriction [30]. These
data support the hypothesis that leukotrienes are more
Percentage of eosinophils in nasal lavage
-5 0 5 10 15
Min-[mean ± 95% CI]-max
FPANS
FPANS plus CTZ
FPANS plus MSK
CTZ plus MSK
PLA
Fig. 3. Data are presented as mean (95% confidence interval, CI) of
percentage of eosinophils in nasal lavage using the values at the end of the
season minus the values before the season. Po0.001 comparing active
treatments vs. placebo and FPANS alone or in combined therapy vs.
cetirizine (CTZ) plus montelukast (MSK). No significant difference was
observed between FPANS in mono-therapy and in combined therapy.
ECP in nasal lavage
−10 −4 2 8 14 20 26
Mean (95% CI) of ECP at the end of season
minus ECP before the season
FPANS
FPANS plus CTZ
FPANS plus MSK
CTZ plus MSK
PLA
Fig. 4. Eosinophil cationic protein (ECP) in nasal lavage. Data are
presented as mean (95% confidence interval, CI) of ECP in nasal lavage
using the values at the end of the season minus the values before the
season. Po0.001 comparing active treatments vs. placebo and FPANS
alone or in combined therapy vs. cetirizine (CTZ) plus montelukast (MSK).
No significant difference was observed between FPANS in mono-therapy
and in combined therapy.
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important mediators in the lower respiratory airways. More
pronounced effects on symptoms of the lower airways (i.e.
bronchostruction) of leukotrienes antagonist may argue that
lower and upper airways respond differently to leukotrienes.
That may explain the modest beneﬁcial effect of a leukotriene
receptor antagonist in our study. On the other hand, it has
been shown that nasal challenge with exogenous leukotrienes
causes nasal congestion, with very limited effects on itching,
sneezing or rhinorrhea [31–33]. One study suggested that 4
weeks of treatment with pranlukast, a leukotriene receptor
antagonist, improved symptoms by only 24% compared with
PLA on week 4 of treatment [34].
In conclusion, FPANS intranasal is highly effective for
treating patients affected by allergic rhinitis, with efﬁcacy
exceeding that of antihistamines and antileukotrienes in
combined therapy. The regular combined therapy of FPANS
with antihistamines or antileukotrienes does not seem to offer
substantial advantage with respect to FPANS in mono-
therapy, in patients affected by seasonal allergic rhinitis,
according to other authors [35]. On the other hand, the daily
cost of anti H1 receptor treatment is 0.53h, whereas the daily
cost of a nasal steroid treatment is 0.63h and the daily cost of
antileukotriene receptor treatment is 2.02h. Therefore, we
think that the combined therapy CTZ and MSK economi-
cally is not proposable as regards the treatment of seasonal
allergic rhinitis, either mild or moderate. Finally, the upper
efﬁcacy of continuous use of intranasal corticosteroids would
reduce health care costs.
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